quick nasdaq list - shelf company, page-2

This traction, if successful, will be very abrupt. So, it is desirable for the current CEO and CFO to remain in the position for at least some time so that any trasitions (including the new CEO and CFO) can be done more smoothly.

We now all know that in ASX, even Biota makes great success in its clinical trials or gets large funding like the U$231m, the market just do not get excited about the company. The coverage of Biota by the market is minimal.

Moving to the US is just for the hope that the situation will change.

Good luck.